Iridium
    Je lijkt een browser te gebruiken die niet wordt ondersteund

    Verouderde browsers kunnen je computer blootstellen aan veiligheidsrisico's. Om onze site optimaal te kunnen gebruiken, moet je upgraden naar een nieuwere browser.

    Voor meer informatie of vragen kan je contact opnemen met CTO via cto(at)gza.be of op het nummer 03 443 37 59.

     

    OPEN VOOR INCLUSIE

     

    30/07/2024 - CAAA617D12302 - An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotidetetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen positive Oligometastatic Prostate Cancer

     

    11/07/2024 - TORPEDO- Stereotactic Body RadioTherapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomized phase II study.

     

    07/03/2024 - SHAPERS- Efficacy and safety of short-course radiotherapy (SCRT) versus total neoadjuvant therapy in older patients with locally advanced rectal cancer: a multicentre open-label, randomised pragmatic clinical trial.

     

    13/12/2023 - Thunder - Treatment of Hig-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial

     

    24/11/2023 - ReCare - ReCare is a cohort within E²-RADIatE and focuses on cancer patients who are treated with high-dose re-irradiation.

     

    27/07/2023 - CASTAR -  CArdiac STereotactic radiation treatment for Ablation of ventRicular tachycardia

     

    08/02/2023 - NARCiS -  Neurocognition after radiotherapy in adult brain and base of skull tumours

     

    06/02/2023 - EFFORT-MICB -  Phase II prospective trial to evaluate the impact of 18F-FDG-PET-CT in stratifying patients with primary muscle invasive bladder cancer and tailoring the treatment accordingly. 

     

    15/03/2022 - SABR-MESCC -Separation surgery followed by Stereotactic Ablative Body Radiotherapy versus Stereotactic Ablative Body Radiotherapy alone for spinal metastases invading the spinal canal: a randomised, non-inferiority trial (SABR-MESCC).

     

    06/10/2021 -PRIMALung-studie - Profylactische cerebrale bestraling of actieve opvolging met magnetische resonantiebeeldvorming bij patiënten met kleincellige longkanker
    (PRIMALung-studie).

     

    29/09/2021 - OligoRARE -Stereotactic bodyradiotherapy in addition to standard of care tretment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial

     

    06/2021 - OligoCare E²-RADIatE -OligoCare: A pragmatic observational cohort study to evaluate radical radiotherapy for oligo-metastatic cancer patients

     

    09/02/2021 - DART- Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial


    25/03/2019 - SAVE- A Phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of andorgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy.


    SBRT LEVERMETASTASEN- National registration of patients with liver metastases treated with stereotactic body radiation therapy.

     

    GESLOTEN VOOR INCLUSIE

     

    06/2020 - IMMUNO SABR- Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non small cell lung cancer.


    02/02/2024 - STAR-TREC - Can we Save the rectum by watchful waiting or TransAnal microsurgery following (chemo)Radiotherapy versus Total mesorectal excision for early Rectal Cancer?

     

    15/02/2022 - PRIMORDIUM -A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients Protocol

     

    22/04/2022 - Neo-Checkray -Neo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9447) in luminal B breast cancer: a phase II randomized trial.

     

    IORT PARTIAL BREAST RT- Oncological outcome and cosmesis after intraoperative partial breast irradiation in early stage breast cancer patients: a prospective observational study.


    25/03-2019 - ROBOMET- Improving quality of life with stereotactic Radiation oncology for Bone metastates.


    04/03/2019 - DOSIS RCT-SPINE SBRT- Dose intensified Image-guided fractionated Stereotactic body radiation therapy for painful spinal metastases versus conventional radiation therapy: a phase II randomised controlled trial


    08/05/2019 - PEGASUS- A Phase 2, Randomized, Open-label, 3-arm Study to Assess the Efficacy and Safety of relacorilant in Combination with Nab-paclitaxel for Patients with Platinum-resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.


    26/01/2021 - DEBIO 1143-301- A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).


    09/2020 - ENGOT-cx11/MK3475-A18- A randomized, phase 3, double-blind study of chemoradiotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer


    09/12/2020 - EORTC1740- Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Maintenance Durvalumab versus Durvalumab plus Radiotherapy followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer


    14/12/2020 - EORTC-1635-BTG- "IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? The I-WOT study"


    13/12/2018 - CHEERS- CHEckpoint inhibition in combination with an immunoboost of External body Radiotherapy in Solid tumors: CHEERS-trial. Een bestralingsboost na 4 cycli immuuntherapie.

    23/10/2018 - EORTC1709- A phase III trial of marizomib in combinaton with standard temozolomide-base radiochemotherapy vs standard temozolomide-base radiochemotherapy alone in patients with newly diagnosed glioblastoma.


    10/08/2018 - STORM- PEACE V: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM)


    11/07/2018 - ROAM-EORTC1308-ROG- Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial.


    30/03/2016 - ATLAS - 56021927PCR3003- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy


    01/01/2016 - ADJ RT BLAASCA UZ GENT- Adjuvant radiotherapy after cystectomy for patients with muscle invasive bladder cancer: a phase II trial.


    • Iridium Netwerk vzw • Oosterveldlaan 22 • 2610 Antwerpen • BE 0885.546.553 RPR Antwerpen • +32 3 443 37 37 • secretariaat@iridiumnetwerk.be • www.iridiumnetwerk.be
      AZ Klina • AZ Monica • AZ Rivierenland • AZ Voorkempen • UZA • Vitaz • ZAS

    • Disclaimer
    • Cookies
    • Privacy